KL 1333
Alternative Names: KL 1333D; KL 1333M; KL1333Latest Information Update: 17 Dec 2024
Price :
$50 *
At a glance
- Originator KT&G Life Sciences
- Developer Abliva; Yungjin Pharm Co
- Class Small molecules
- Mechanism of Action Nicotinamide adenine dinucleotide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Mitochondrial disorders
- No development reported Diabetes mellitus